Allovir Stock Valuation

ALVR
 Stock
  

USD 7.51  0.34  4.74%   

How much is Allovir worth today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Allovir, is its stock price multiplied by the total number of shares outstanding, calculating Allovir's enterprise value requires a different approach. It uses Allovir's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Allovir shows a prevailing Real Value of $16.09 per share. The current price of the firm is $7.51. At this time, the firm appears to be undervalued. Our model approximates the value of Allovir from analyzing the firm fundamentals such as Current Valuation of 435.82 M, return on equity of (83.35) %, and Shares Owned by Insiders of 50.01 % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor buying undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
  
Allovir Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Allovir's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Allovir Most Recent Valuation Data

Price Book
2.7
Enterprise Value
441.4 M
Enterprise Value Ebitda
(2.38) 
Undervalued
Today 7.51
Please note that Allovir's price fluctuation is somewhat reliable at this time. Calculation of the real value of Allovir is based on 3 months time horizon. Increasing Allovir's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Allovir is useful when determining the fair value of the Allovir stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Allovir. Since Allovir is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Allovir Stock. However, Allovir's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
16.09
Real Value
21.42
Upside
Estimating the potential upside or downside of Allovir helps investors to forecast how Allovir stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Allovir more accurately as focusing exclusively on Allovir's fundamentals will not take into account other important factors:
Earnings
Estimates (3)
LowProjected EPSHigh
-2.73-2.64-2.57
Details
Hype
Prediction
LowEstimated ValueHigh
2.187.5112.84
Details
Naive
Forecast
LowNext ValueHigh
1.727.0512.38
Details
4 Analysts
Consensus
LowTarget PriceHigh
32.0042.7555.00
Details

Allovir Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Allovir's current stock value. Our valuation model uses many indicators to compare Allovir value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Allovir competition to find correlations between indicators driving Allovir's intrinsic value. More Info.
Allovir is number one stock in beta category among related companies. It is rated second in price to book category among related companies fabricating about  2.14  of Price to Book per Beta. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Allovir by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Allovir's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Allovir's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Allovir's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Allovir and how it compares across the competition.

About Allovir Valuation

The stock valuation mechanism determines the current worth of Allovir on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Allovir. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Allovir based exclusively on its fundamental and basic technical indicators. By analyzing Allovir's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Allovir's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Allovir. We calculate exposure to Allovir's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Allovir's related companies.
Fiscal Year End
December
Industry
Biotechnology
Concentration
Biotechnology
Full Time Employees
107.0
Service Category
Biotechnology
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people.

Allovir Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Allovir does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio8.00
Enterprise Value To Ebitda-2.31
Please continue to Trending Equities. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
653.1 M
Return On Assets
(0.38) 
Return On Equity
(0.72) 
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.